Literature DB >> 26811653

Advanced gastric cancer: What we know and what we still have to learn.

Federico Coccolini1, Giulia Montori1, Marco Ceresoli1, Simona Cima1, Maria Carla Valli1, Gabriela E Nita1, Arianna Heyer1, Fausto Catena1, Luca Ansaloni1.   

Abstract

Gastric cancer is a common neoplastic disease and, more precisely, is the third leading cause of cancer death in the world, with differences amongst geographic areas. The definition of advanced gastric cancer is still debated. Different stadiating systems lead to slightly different stadiation of the disease, thus leading to variations between the single countries in the treatment and outcomes. In the present review all the possibilities of treatment for advanced gastric cancer have been analyzed. Surgery, the cornerstone of treatment for advanced gastric cancer, is analyzed first, followed by an investigation of the different forms and drugs of chemotherapy and radiotherapy. New frontiers in treatment suggest the growing consideration for intraperitoneal administration of chemotherapeutics and combination of traditional drugs with new ones. Moreover, the necessity to prevent the relapse of the disease leads to the consideration of administering intraperitoneal chemotherapy earlier in the therapeutical algorithm.

Entities:  

Keywords:  Advanced gastric cancer; Chemotherapy; Definition; Hypertermic intraperitoneal chemotherapy; Intraperitoneal; Surgery

Mesh:

Substances:

Year:  2016        PMID: 26811653      PMCID: PMC4716026          DOI: 10.3748/wjg.v22.i3.1139

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  126 in total

1.  Nodal dissection for patients with gastric cancer: a randomised controlled trial.

Authors:  Chew-Wun Wu; Chao A Hsiung; Su-Shun Lo; Mao-Chin Hsieh; Jen-Hao Chen; Anna Fen-Yau Li; Wing-Yiu Lui; Jacqueline Whang-Peng
Journal:  Lancet Oncol       Date:  2006-04       Impact factor: 41.316

Review 2.  Current status of novel agents in advanced gastroesophageal adenocarcinoma.

Authors:  Nishi Kothari; Khaldoun Almhanna
Journal:  J Gastrointest Oncol       Date:  2015-02

Review 3.  A meta-analysis of robotic versus laparoscopic gastrectomy for gastric cancer.

Authors:  Wei-Song Shen; Hong-Qing Xi; Lin Chen; Bo Wei
Journal:  Surg Endosc       Date:  2014-05-02       Impact factor: 4.584

4.  Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.

Authors:  Johan L Dikken; Edwin P M Jansen; Annemieke Cats; Berdine Bakker; Henk H Hartgrink; Elma Meershoek-Klein Kranenbarg; Henk Boot; Hein Putter; Koen C M J Peeters; Cornelis J H van de Velde; Marcel Verheij
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

5.  Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer.

Authors:  Mi Sun Kim; Joon Seok Lim; Woo Jin Hyung; Yong Chan Lee; Sun Young Rha; Ki Chang Keum; Woong Sub Koom
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

6.  Early cancer of the stomach.

Authors:  T Murakami
Journal:  World J Surg       Date:  1979-11       Impact factor: 3.352

7.  Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group.

Authors:  A Cuschieri; P Fayers; J Fielding; J Craven; J Bancewicz; V Joypaul; P Cook
Journal:  Lancet       Date:  1996-04-13       Impact factor: 79.321

8.  Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG).

Authors:  I Songun; H J Keizer; J Hermans; P Klementschitsch; J E de Vries; J A Wils; J van der Bijl; J H van Krieken; C J van de Velde
Journal:  Eur J Cancer       Date:  1999-04       Impact factor: 9.162

9.  Extended lymph-node dissection for gastric cancer.

Authors:  J J Bonenkamp; J Hermans; M Sasako; C J van de Velde; K Welvaart; I Songun; S Meyer; J T Plukker; P Van Elk; H Obertop; D J Gouma; J J van Lanschot; C W Taat; P W de Graaf; M F von Meyenfeldt; H Tilanus
Journal:  N Engl J Med       Date:  1999-03-25       Impact factor: 91.245

10.  Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501.

Authors:  Takeshi Sano; Mitsuru Sasako; Seiichiro Yamamoto; Atsushi Nashimoto; Akira Kurita; Masahiro Hiratsuka; Toshimasa Tsujinaka; Taira Kinoshita; Kuniyoshi Arai; Yoshitaka Yamamura; Kunio Okajima
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

View more
  25 in total

1.  Overall and disease-free survival in patients treated with CRS + HIPEC with cisplatin and paclitaxel for gastric cancer with peritoneal carcinomatosis.

Authors:  Paola Fugazzola; Federico Coccolini; Giulia Montori; Marco Ceresoli; Paolo Baggi; Antonio Costanzo; Matteo Tomasoni; Francesco Gregis; Silvia Nozza; Luca Ansaloni
Journal:  J Gastrointest Oncol       Date:  2017-06

2.  DLX6-AS1 promotes cell proliferation, migration and EMT of gastric cancer through FUS-regulated MAP4K1.

Authors:  Qiong Wu; Jiali Ma; Wenying Meng; Pingping Hui
Journal:  Cancer Biol Ther       Date:  2019-10-08       Impact factor: 4.742

Review 3.  The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer.

Authors:  Jacopo Desiderio; Joseph Chao; Laleh Melstrom; Susanne Warner; Federico Tozzi; Yuman Fong; Amilcare Parisi; Yanghee Woo
Journal:  Eur J Cancer       Date:  2017-04-26       Impact factor: 9.162

4.  Immunoscore is a strong predictor of survival in the prognosis of stage II/III gastric cancer patients following 5-FU-based adjuvant chemotherapy.

Authors:  Sumi Yun; Jiwon Koh; Soo Kyung Nam; Yoonjin Kwak; Sang-Hoon Ahn; Joong Do Park; Hyung-Ho Kim; Woo Ho Kim; Hye Seung Lee
Journal:  Cancer Immunol Immunother       Date:  2020-08-12       Impact factor: 6.968

5.  Depletion of Circular RNA circ_CORO1C Suppresses Gastric Cancer Development by Modulating miR-138-5p/KLF12 Axis.

Authors:  Yongqiang Fan; Min Liu; Anquan Liu; Nailing Cui; Zhimei Chen; Qian Yang; Aihua Su
Journal:  Cancer Manag Res       Date:  2021-05-11       Impact factor: 3.989

6.  Inductions of Caspase-, MAPK- and ROS-dependent Apoptosis and Chemotherapeutic Effects Caused by an Ethanol Extract of Scutellaria barbata D. Don in Human Gastric Adenocarcinom Cells.

Authors:  Ji Hwan Shim; Huijin Gim; Soojin Lee; Byung Joo Kim
Journal:  J Pharmacopuncture       Date:  2016-06

7.  CA125 is a potential biomarker to predict surgically incurable gastric and cardia cancer: A retrospective study.

Authors:  Taobo Luo; Wenhu Chen; Lifang Wang; Hongguang Zhao
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

8.  Effect of laparoscopic gastrectomy on compliance with adjuvant chemotherapy in patients with gastric cancer.

Authors:  Huizheng Bao; Na Xu; Zhongkun Li; Hongtao Ren; Hong Xia; Na Li; Hao Yu; Janbiao Wei; Chengyi Jiang; Lu Liu
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

9.  Delta-radiomics and response to neoadjuvant treatment in locally advanced gastric cancer-a multicenter study of GIRCG (Italian Research Group for Gastric Cancer).

Authors:  Maria Antonietta Mazzei; Letizia Di Giacomo; Giulio Bagnacci; Valerio Nardone; Francesco Gentili; Gabriele Lucii; Paolo Tini; Daniele Marrelli; Paolo Morgagni; Gianni Mura; Gian Luca Baiocchi; Frida Pittiani; Luca Volterrani; Franco Roviello
Journal:  Quant Imaging Med Surg       Date:  2021-06

10.  Preventive effect of Oenothera rosea on N-methyl-N-nitrosourea-(NMU) induced gastric cancer in rats.

Authors:  Yuan Almora-Pinedo; Jorge Arroyo-Acevedo; Oscar Herrera-Calderon; Víctor Chumpitaz-Cerrate; Renán Hañari-Quispe; Aldo Tinco-Jayo; Cesar Franco-Quino; Linder Figueroa-Salvador
Journal:  Clin Exp Gastroenterol       Date:  2017-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.